A Randomized and Prospective Study Comparing Treatment With High-Dose Intravenous Immunoglobulin With Monoclonal Antibodies for Rescue of Kidney Grafts With Steroid-Resistant Rejection

Casadei, Domingo; Rial, María del Carmen; Opelz, Gerhard; Golberg, Julio C.; Argento, J; Greco, Gabriela; Guardia, Olga; Haas, E; Raimondi, Eduardo

doi:10.1097/00007890-200101150-00009

Cited by 129 publications

(75 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pretreatment with IVIg results in reductions of anti-HLA antibodies and is effective in treatment of allograft rejection episodes (10,28,29). The high-dose IVIg protocol that was developed at Cedars-Sinai evolved from re-ported efficacy with other inflammatory disorders (e.g., Kawasaki disease) (14).…”

Section: Clinical Use Of Ivig In Kidney Transplantationmentioning

confidence: 99%

Presensitization

Jordan¹,

Pescovitz²

2006

Clinical Journal of the American Society of Nephrology

110

View full text Add to dashboard Cite

Much attention has been placed recently on transplantation in highly HLA-sensitized patients. In attempts to remove these antibodies and enable successful transplantation, several novel approaches have been developed. These include intravenous Ig (IVIg), mycophenolate mofetil, sirolimus, alemtuzumab, protein A immunoabsorption, and rituximab. IVIg has emerged as a very effective agent when used alone in high dose or when used in low dose and combined with plasmapheresis. Although alemtuzumab has been used to eliminated B cells, it fails to prevent antibody-mediated rejection and therefore probably is not suitable for desensitization. Rituximab, a B cell-specific antibody, seems to be safe and to have some efficacy as a sole agent in elimination of alloantibodies but most likely will require combination therapy with IVIg or other agents. Newer agents, such as humanized anti-CD20, are being developed. Despite the great interest in the problem of allosensitization, with one notable exception, there is a major deficiency in controlled clinical trials, the conduct of which should be a focus for the near future.

show abstract

Section: Clinical Use Of Ivig In Kidney Transplantationmentioning

confidence: 99%

Presensitization

Jordan¹,

Pescovitz²

2006

Clinical Journal of the American Society of Nephrology

110

View full text Add to dashboard Cite

show abstract

“…In addition, IVIG are effective in the treatment of steroid-resistant acute rejections after kidney transplantation (5,6). It is unknown whether IVIG are effective as prophylaxis for acute rejection after organ transplantation.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B Immunoglobulins Inhibit Dendritic Cells and T Cells and Protect Against Acute Rejection After Liver Transplantation

Kwekkeboom¹,

Tha-In²,

Tra³

et al. 2005

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Early studies showed that IVIG was as effective as OKT3 in reversing steroidresistant acute rejection episodes (Casadei et al, 2001). In the setting of antibody-mediated rejection, IVIG has been shown to be beneficial when used in conjunction with plasmapheresis and/or rituximab (Lefaucher et al, 2009;Shehata et al, 2010).…”

Section: Applicationsmentioning

confidence: 99%